Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
BMC Cardiovasc Disord ; 14: 169, 2014 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-25425404

RESUMEN

BACKGROUND: Glucose-insulin-potassium (GIK) has been advocated in the setting of acute coronary syndrome (ACS) to reduce ischemia-related arrhythmias and myocardial injury. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess whether the use of GIK infusions >3 or <3 hours after the onset of symptoms reduce mortality or cardiac arrest. METHODS: Electronic databases (Medline, EMBASE, and Cochrane Central Register of Controlled Trials) and references of retrieved articles were searched for RCTs evaluating the effect of GIK infusions, <3 hours or >3 hours after the onset of symptoms, on mortality and/or cardiac arrest. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each outcome. RESULTS: Nine trials were identified and eligible for review. The summary OR for in-hospital mortality was 1.01 (95% CI 0.94 to 1.09), based on 2,542 deaths among 27,294 patients. The subgroup analysis according to the study enrollment time (within 3 hours [OR, 0.77, 95% CI 0.50-1.16], vs. >3 hours [OR, 0.90; 95% CI, 0.67-1.21]) did not reveal any difference in mortality. CONCLUSIONS: Administration of GIK in ACS patients does not significantly reduce mortality whether or not GIK administration >3 or <3 hours after the onset of symptoms.


Asunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Soluciones Cardiopléjicas/administración & dosificación , Paro Cardíaco/prevención & control , Ensayos Clínicos Controlados Aleatorios como Asunto , Síndrome Coronario Agudo/complicaciones , Síndrome Coronario Agudo/mortalidad , Soluciones Cardiopléjicas/efectos adversos , Distribución de Chi-Cuadrado , Esquema de Medicación , Glucosa/administración & dosificación , Glucosa/efectos adversos , Paro Cardíaco/etiología , Paro Cardíaco/mortalidad , Mortalidad Hospitalaria , Humanos , Infusiones Parenterales , Insulina/administración & dosificación , Insulina/efectos adversos , Oportunidad Relativa , Potasio/administración & dosificación , Potasio/efectos adversos , Factores de Riesgo , Factores de Tiempo , Tiempo de Tratamiento , Resultado del Tratamiento
2.
BMC Cell Biol ; 13: 23, 2012 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-22928917

RESUMEN

BACKGROUND: Ovarian hyper stimulation syndrome (OHSS) is an iatrogenic complication associated with fertility drugs. It is characterized by increased vascular permeability and substantial fluid shift with accumulation in the body cavity. The pathogenesis of OHSS remains obscure, and no definitive treatments are currently available. RESULTS: Using western blot and short-circuit current (Isc) techniques, we investigate the potential coactions of analysis in cystic fibrosis transmembrane conductance regulator (CFTR) and aquaporin 1 (AQP1) on the hyper permeability of body cavity peritoneal epithelial cells in the pathogenesis of OHSS. The rats develop OHSS symptoms, with the up regulation of both CFTR and AQP1 expression and enhanced CFTR channel activity in peritoneal epithelial cells, can also be mimicked by administration of estrogen, alone in ovariectomized rats. Administration of progesterone suppresses CFTR activity, OHSS symptoms as well as CFTR and AQP1 expression. Besides, AQP1 inhibitor, HgCl(2), can suppress CFTR channel activity. Therefore, antisera against CFTR or AQP1 to OHSS animals may result in alleviation of the symptom. CONCLUSION: This study confirms the coactions of CFTR and AQP1 play a critical role in the development and progression of increased peritoneal epithelial permeability in severe OHSS. These findings may provide grounds for ameliorating assisted reproduction treatment strategy to reduce the risk of OHSS in in vitro fertilization (IVF).


Asunto(s)
Acuaporina 1/metabolismo , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Células Epiteliales/efectos de los fármacos , Estrógenos/farmacología , Síndrome de Hiperestimulación Ovárica/metabolismo , Animales , Acuaporina 1/antagonistas & inhibidores , Permeabilidad de la Membrana Celular/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Células Epiteliales/metabolismo , Femenino , Cloruro de Mercurio/farmacología , Síndrome de Hiperestimulación Ovárica/etiología , Progesterona/farmacología , Ratas , Ratas Sprague-Dawley , Regulación hacia Arriba/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA